case_images: PMC11707501_01
case_images: (A) Abdominal computed tomography scan indicating a mass of 2 cm in size (black circle); (B) magnetic resonance imaging illustrating a mass consistent with renal cell carcinoma (black circles indicate renal cell carcinoma).
case_images: mi-05-02-00211-g00.jpg
case_images: PMC11707501_01_mi-05-02-00211-g00.jpg
case_images: f1-MI-5-2-00211
case_images: A whole-body computed tomography (CT) scan revealed a mass 2 cm in size in the right kidney (Fig. 1A). Magnetic resonance imaging of the mass suggested renal cell carcinoma (RCC) (Fig. 1B).
case_images: FDG PET/CT scans, performed (A) before and (B) after R-CHOP treatment, taken 3 months apart, illustrating the metabolic response of the lymphoma, with a decrease in the previously diffuse increase in FDG uptake in the inguinal lymph nodes (indicated by black circles). The diffuse FDG uptake in the intestine observed on (A) the first PET/CT scan was attributed to metformin use. FDG, fludeoxyglucose-18; PET, positron emission tomography; CT, computed tomography.
case_images: mi-05-02-00211-g01.jpg
case_images: PMC11707501_01_mi-05-02-00211-g01.jpg
case_images: f2-MI-5-2-00211
case_images: A fludeoxyglucose-18 (FDG) positron emission tomography (PET)CT scan was requested, and the results were consistent with lymphoma (Fig. 2A). A second FDG PET/CT was ordered, and the patient exhibited a complete response after two cycles of R-CHOP treatment (Fig. 2B).